Charles Schwab’s Asterias Biotherapeutics Inc. Series A AST Stock Holding History

Charles Schwab’s Portfolio AST Stock Details AST Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-45,825	Closed	-$67K	–	3230
2018 Q1	$67K	Hold	45,825	–	–	﹤0.01%	3061
2017 Q4	$104K	Hold	45,825	–	–	﹤0.01%	3032
2017 Q3	$156K	Hold	45,825	–	–	﹤0.01%	3041
2017 Q2	$163K	Hold	45,825	–	–	﹤0.01%	3060
2017 Q1	$156K	Hold	45,825	–	–	﹤0.01%	2966
2016 Q4	$211K	Buy	45,825 +30,700	+203%	+$127K	﹤0.01%	2950
2016 Q3	$65K	Hold	15,125	–	–	﹤0.01%	3022
2016 Q2	$37K	Hold	15,125	–	–	﹤0.01%	3084
2016 Q1	$72K	Hold	15,125	–	–	﹤0.01%	3016
2015 Q4	$60K	Hold	15,125	–	–	﹤0.01%	3065
2015 Q3	$59K	Hold	15,125	–	–	﹤0.01%	3062
2015 Q2	$70K	Buy	+15,125	New	+$145K	﹤0.01%	3065

Other funds holding AST

Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

NFC

Northeast Financial Consultants Westport, Connecticut $2.45B AUM 15.14% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Thrivent Financial for Lutherans Minneapolis, Minnesota $52.5B AUM 27.12% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Creative Planning Overland Park, Kansas $147B AUM 18.73% 1-Year Est. Return

ECM

Element Capital Management New York $1.05B AUM 5.05% 1-Year Est. Return

Paloma Partners Greenwich, Connecticut $510M AUM 286.05% 1-Year Est. Return

Charles Schwab's AST Position: Q2 2018 in Review

Charles Schwab sold out of Asterias Biotherapeutics Inc. Series A (AST) in Q2 2018, closing a stake of 45,825 shares — an estimated $67K sold.

Charles Schwab first reported a position in AST in Q2 2015 and held it in 12 quarters. The position peaked at $211K in Q4 2016. 62 funds tracked by Wall St. Rank hold AST as of Q2 2018.

Charles Schwab reported no remaining Asterias Biotherapeutics Inc. Series A position as of Q2 2018 after selling out during the quarter.
Charles Schwab sold 45,825 Asterias Biotherapeutics Inc. Series A shares in Q2 2018, an estimated $67K.
Charles Schwab first reported a position in Asterias Biotherapeutics Inc. Series A in Q2 2015 and held it in 12 quarters.
Charles Schwab's Asterias Biotherapeutics Inc. Series A position peaked at $211K in Q4 2016.
62 funds tracked by Wall St. Rank held Asterias Biotherapeutics Inc. Series A as of Q2 2018.

Based on Charles Schwab's 13F filing for Q2 2018, filed 8 Aug 2018.